1) Clark MS, Smith PO, Jamieson B:FPIN's clinical inquiries:Antidepressants for the treatment of insomnia in patients with depression. Am Fam Physician 84:1-2, 2011
2) Fagiolini A, Comandini A, Catena Dell' Osso M, et al:Rediscovering trazodone for the treatment of major depressive disorder. CNS Drugs 26:1033-1049, 2012
3) Hermes EDA, Sernyak M, Rosenheck R:Use of second-generation antipsychotic agents for sleep and sedation:A provider survey. Sleep 36:597-600, 2013
4) 井原裕:薬の前に療養指導.精神科治療学27:171-178,2012
5) 稲垣中,中川敦夫,吉尾隆:診療録データなどを用いた向精神薬処方に関する実態調査研究.(2)抗不安薬・睡眠薬の処方実態.平成22年度厚生労働科学研究費補助金(厚生労働科学特別研究事業)「向精神薬の処方実態に関する国内外の比較研究(研究代表者和田清)」研究報告書.pp45-56, 2011
6) 厚生労働省:11月29日中医協総会「個別事項(その2:精神医療)について」http://www.mhlw.go.jp/file/05-Shingikai-12404000-Hokenkyoku-Iryouka/0000031076.pdf
7) 松本俊彦,尾崎茂,小林桜児,他:わが国における最近の鎮静剤(主としてベンゾジアゼピン系薬剤)関連障害の実態と臨床的特徴―覚せい剤関連障害との比較.精神経誌113:1184-1198, 2011
8) Mojtabai R, Olfson M:National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry 67:26-36, 2010
9) 日本睡眠学会:睡眠薬の適正な使用と休薬のためのガイドライン.http://www.jssr.jp/data/pdf/suiminyaku-guideline.pdf
10) 尾崎茂:抗不安薬・睡眠薬の依存.臨床精神医学42:1111-1115, 2013
11) Roth AJ, McCall WV, Liguori A:Cognitive, psychomotor and polysomnographic effects of trazodone in primary insomniacs. J Sleep Res 20:552-558, 2011
12) Stahl SM:Mechanism of action of trazodone:A multifunctional drug. CNS Spectr 14:536-546, 2009
13) Weisler R, McIntyre RS, Bauer M:Extended-release quetiapine fumarate in the treatment of patients with major depressive disorder:Adjunct therapy. Expert Rev Neurother 13:1183-1200, 2013
14) Yatham LN, Kennedy SH, Parikh SV, et al:Canadian Network for Mood and Anxiety Treatments(CANMAT)and International Society for Bipolar Disorders(ISBD)collaborative update of CANMAT guidelines for the management of patients with bipolar disorder:Update 2013. Bipolar Disord 15:1-44, 2013